CC-90011 + abiraterone + prednisone

**CC-90011 + abiraterone + prednisone** is a combination regimen investigated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). - **CC-90011** is an oral, potent, selective, and reversible inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A), an epigenetic regulator implicated in tumorigenesis. It acts by increasing expression of tumor suppressor genes and decreasing expression of tumor-promoting genes, thereby reducing tumor cell growth[1][2][5]. - **Abiraterone** is an androgen biosynthesis inhibitor, specifically a CYP17A1 inhibitor, which decreases androgen production, thereby inhibiting androgen receptor (AR) activation and tumor growth in prostate cancer. - **Prednisone** is a synthetic glucocorticoid that is frequently co-administered with abiraterone to reduce its mineralocorticoid side effects and potentially provide anti-inflammatory/anti-cancer effects. This combination is being investigated to assess whether CC-90011 can re-sensitize mCRPC tumors to anti-androgen therapy by modulating AR pathway activity[2][3][5].

Other names

pulrodemstat + abiraterone + prednisone